04:23 AM EDT, 04/01/2025 (MT Newswires) -- Quantum Biopharma ( QNTM ) said Tuesday it entered into a joint clinical study with the Massachusetts General Hospital to investigate an imaging technique to monitor demyelination in people suffering from multiple sclerosis.

The parties aims to validate a novel positron emission tomography, or PET, biomarker to monitor myelin integrity and measure demyelination. Multiple sclerosis is a chronic disease of the central nervous system.

The financial terms of the collaboration weren't disclosed.